Retension Pharmaceuticals, Inc. (RTSN)
NASDAQ: RTSN · Real-Time Price · USD
15.50
+0.50 (3.33%)
At close: Oct 22, 2026, 4:00 PM EDT
16.38
+0.88 (5.68%)
After-hours: Oct 22, 2026, 7:50 PM EDT
Company Description
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling.
The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease.
The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
Retension Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2023 |
| IPO Date | Oct 9, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Eric Keller |
Contact Details
Address: 1104 West Broad Street #1029 Falls Church, Virginia 22046 United States | |
| Phone | (703) 940-9761 |
| Website | retensionpharmaceuticals.com |
Stock Details
| Ticker Symbol | RTSN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 2002988 |
| CUSIP Number | 76135H100 |
| ISIN Number | US76135H1005 |
| Employer ID | 93-2592788 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric Keller, J.D. | Chief Executive Officer and Director |
| Alex Schwartz | Chief Financial Officer |
| Paul Sweetnam, Ph.D. | Chief Scientific Officer |
| Alison D. Schecter, M.D. | Chief Medical Officer |
| Sabine Bisson, Ph.D. | Chief Operating Officer |
| Michael Joseph Berendt, Ph.D. | Executive Chairman |
| Franklin M. Berger | Director |
| Donald Olds, M.B.A. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | SCHEDULE 13G | Filing |
| Oct 16, 2026 | SCHEDULE 13G | Filing |
| Oct 15, 2026 | SCHEDULE 13G | Filing |
| Oct 14, 2026 | SCHEDULE 13D | Filing |
| Oct 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 9, 2026 | 424B4 | Prospectus |
| Oct 8, 2026 | EFFECT | Notice of Effectiveness |
| Oct 8, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Oct 8, 2026 | CERT | Certification by an exchange approving securities for listing |